Premium
P1–447: Pharmacological MRI of H3 receptor antagonist GSK189254 in the rat brain
Author(s) -
Cash Diana,
Tilling Lorna,
Barjat Herve,
Debnam Allison,
Njeri Catherine J.,
Briggs Mike A.,
Roberts Jenny C.,
Medhurst Andy D.,
Irving Elaine A.,
Williams Steve C.R.,
Upton Neil,
James Michael F.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.826
Subject(s) - histamine h3 receptor , neuroscience , antagonist , pharmacology , medicine , chemistry , anesthesia , psychology , receptor
Purpose: To evaluate the safety and efficacy of oxcarbazepine in the treatment of Alzheimer’s disease (AD) patients who exhibit hypersexual behavior. Methods: In a cross-sectional study, all patients with AD being treated with oxcarbazepine for hypersexual behaviors were evaluated. All patients resided in a special care unit as part of an assisted living facility. All participants fulfilled the DSM-IV and NINCDS-ADRDA criteria for possible AD. There were no exclusion criteria. Treatment was started at 150 mg/day, and if no improvement, the dose was titrated by 150 mg/day in two divided doses. Titration stopped once the patient’s behavior was controlled, or a maximum dose of 900 mg/day was reached. Follow up blood chemistries for possible hyponatremia were performed bi-monthly. Results: Eleven male patients were evaluated. All received other medications to control hypersexual behavior prior to the study. Information regarding each patient’s behavioral status was obtained from employed caregivers at the assisted living facility. Caregivers were certified nurse aides who had direct patient contact and covered a 24 hour period of time. Four of the patients evaluated also demonstrated occasional aggressive behaviors. Efficacy was reported in all patients after two weeks of treatment. Average effective dose for treatment was 600 750 mg/day in two divided doses. No adverse events were reported. Blood chemistries were unchanged. Conclusion: Oxcarbazepine treatment for hypersexual behavior in AD patients was effective and well tolerated.